Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
not primarily appetite-driven (OUP Academic) Expected weight loss (this is where many people get misled) In major obesity trials: Semaglutide 2.4 mg weekly: ~14.9% mean weight loss at 68 weeks (STEP-1) (PubMed) Tirzepatide: ~15.0% to ~20.9% mean weight loss at 72 weeks , dose-dependent (SURMOUNT-1) (PubMed) AOD-9604s best-known human signal is kilograms, not double-digit percentages , and later studies did not sustain a strong obesity-drug profile
However, these delivery systems are not yet standard in most commercial products, meaning the GHK-Cu concentration listed on a product label does not necessarily translate to the bioavailable dose reaching dermal fibroblasts
Persistent use for 2-4 weeks can obviously improve scalp oil balance and reduce hair fall
Ganther HE (1971)
Physicians who prescribe unauthorized health products face potential disciplinary action including license loss
